Boji Pharmaceutical said at an investor conference call on the 27th that in the first three quarters of 2026, the company's independent R&D and technological achievement transformation services generated 11.5 million yuan. It is expected that it will continue to generate related revenue in the future, and the gross margin of this business is high. Currently, the company has several projects to be transferred, which will bring positive contributions to the company's performance in the future.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.